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Abstract
Background The purpose of our study was to determine
whether abnormalities of increased or decreased fundus
autofluorescence (FAF) are associated with local changes in
macular pigment (MP) optical density in patients with age-
related maculopathy (ARM) and macular degeneration
(ARMD).
Methods FAF imaging and MP measurement was per-
formed through dilated pupils using a modified confocal
scanning laser ophthalmoscope (HRA, Heidelberg Engi-
neering, Germany) according to a standard protocol. Two-
wavelength autofluorescence method was employed for
determination of local macular pigment optical density
(LMPOD). Image analysis and measurement of LMPOD
at the area of altered FAF was performed using Heidelberg
Eye Explorer Software. Mean values of LMPOD at the
site of FAF abnormality were compared to an adjacent
location with normal background FAF of the same image.
Results Sixty-three eyes of 63 patients (28 male, 35 female,
mean age 75.8±8.8 years) were included in this analysis.
Group 1 comprised 31 cases with focal increased FAF.
Mean LMPOD in the area of increased FAF was 0.073±
0.083 compared to 0.075±0.074 in the adjacent area of
normal FAF. Group 2 comprised 32 cases of focal
decreased FAF. Mean LMPOD in the area of decreased
FAF was –0.004±0.088 compared 0.053±0.075 in the
adjacent area of normal FAF. The site of increased FAF
showed no significant difference in LMPOD (p=0.927)
compared to adjacent areas of normal FAF, while areas of
decreased FAF revealed significantly lower LMPOD
(p=0.001) compared to adjacent areas of normal FAF.
Conclusions Focal increases of FAF due to ARM or
ARMD did not lead to change in LMPOD. Presumably,
retinal layers containing MP are unaffected by these
processes. For lesions exhibiting focal decreased FAF, a
reduction of LMPOD cannot be excluded. Further studies
are needed to investigate MP in the course of disease.
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Introduction
The human and economic impact of age-related macular
degeneration (ARMD) in Western societies is enormous
[1–3]. While current research efforts aim at therapeutic
approaches and preventive measures, the underlying mo-
lecular mechanisms of pathogenesis remain poorly under-
stood. The retinal pigment epithelium (RPE) and its
dysfunction seem to play a key role in the development
and throughout the course of the disease [4, 5]. With the
advent of confocal scanning laser ophthalmoscopy, in vivo
imaging of fundus autofluorescence (FAF) became avail-
able [6, 7]. Since retina autofluorescence is mainly derived
from lipofuscin fluorophores [8, 9], this method is a valid
tool for retinal evaluation, providing additional information
on RPE viability and function. Earlier studies described
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FAF changes in early age-related maculopathy (ARM) and
in atrophic ARMD [7, 10]. By classification of distinct
patterns of altered FAF, prognostic information on disease
course and progression can be identified [11, 12].
In relation to age-related macular disease, the macular
pigment (MP) was in the focus of research interest and
continually investigated over the last decade [13–17]. Its
putative protective role is based on a unique combination of
its chemical, physical, and anatomical properties. The three
carotenoids lutein (L), zeaxanthin (Z), and meso-zeaxanthin
are the main constituents of MP. With the highest density of
MP in the fovea, its concentration decreases sharply within
the first degrees of eccentricity. However, at low levels, L
and Z are present throughout the periphery of the retina.
The cumulated amount of L and Z of the periphery
accounts for roughly half of the central accumulation [18,
19]. MP density shows a wide variability of absolute
amount and distribution of macular L and Z between
individuals and during the course of disease [20].
The autofluorescence method of MP measurement [20,
21] uses two wavelengths for FAF excitation. The short
wavelength is highly absorbed by MP, the long wavelength
is only marginally attenuated. Thus, by subtracting both
FAF intensities, a distribution map of MP can be calculated
and used for further analysis.
Measurement of MP by FAF imaging could be influenced
by local variation of autofluorescence intensity. Additionally,
an area of disturbed RPE (e.g., local abnormal autofluor-
escence) could influence the MP density at this site. We
therefore investigated local macular pigment optical density
(LMPOD) at the location of circumscribed FAF changes.
Methods
Participants of the prospective observational study “The
Role of Macular Pigment in Patients With Age-related
Macular Degeneration” (ClinicalTrials.gov Identifier:
NCT00494325) were recruited for this cross-sectional
study. Inclusion criteria were age>50 years, presence of
soft or confluent drusen or an area of geographic atrophy,
clear optical media, image quality sufficient for analysis,
and the presence of localized areas of well-demarcated
abnormal FAF. The study eye was chosen by the criteria of
FAF image quality (i.e., sharpness of lesion demarcation).
Diagnosis and stage of disease was assessed by
biomicroscopy and 30° color fundus photography (FF 450
plus, Carl Zeiss Meditec, Jena, Germany).
The circumscribed lesions of increased and decreased
FAF brightness were divided into group 1 and group 2,
respectively. In case either FAF abnormalities were found in
one eye, the better demarcated and more centrally located
was chosen over the other for the group allocation.
Before examination, drops containing 0.5% tropicamide
and 2.5% phenylephrine were applied to the study eye for a
pupil diameter dilation of 6 mm or greater.
Prior to examination, informed written consent was
obtained after explanation of the nature of and possible
risks of our study. The research followed the tenets of the
Declaration of Helsinki and Institutional Review Board
approval was granted.
MP measurements were obtained with a modified
confocal scanning laser ophthalmoscope (mpHRA, Heidel-
berg Engineering, Heidelberg, Germany) [20] using auto-
fluorescence images obtained at two excitation-wavelength
based on the pioneering work of Delori et al. [21].
All images for the analysis were acquired through dilated
pupils. Subjects were positioned in front of a tabletop and
instructed to look straight ahead and to remain steady, and
20° autofluorescence images of the posterior pole at
512 x 512 pixels were obtained at excitation wavelengths
of 488 nm and 514 nm. From a sequence of nine single
frames, a non-normalized mean image was calculated. A
bandpass filter with a short wavelength cut-off at 530 nm
was used for the detection of FAF, as shown in Fig. 1.
Since the absorbance of MP at 488-nm wavelength is
high, and at 514 nm close to zero, excitation laser light was
selectively attenuated by the properties of MP as shown in
Fig. 1. Thus, based on differential absorption, the single-
pass optical density of MP can be calculated from log FAF
images at both excitation wavelengths as previously
described [22]. For further analysis, a map displaying the
MP optical density in a range of gray values from 0 to 255
was used.
FAF images (488-nm excitation wavelength) were
analyzed for lesions of focal increased or decreased FAF.
Lesions were identified in contrast to the FAF intensity of a
visually unaffected area with homogenous signal of
Fig. 1 Absorbance spectrum of macular pigment (yellow) with a
maximum absorbance at 460 nm. Excitation wavelengths at 488 nm
and 514 nm, barrier filter at 530 nm, imaging by detection of
lipofuscin autofluorescence (AF) at 620 to 630-nm wavelengths
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background FAF. Areas of altered FAF were marked using
the overlay tool of the Heidelberg Eye Explorer Software
Version 1.6.2. Concurrently, an unaffected area with
homogenous signal of normal background FAF with similar
size and eccentricity and adjacent to the alteration was
identified and circumnavigated in the same manner. Then,
overlays of both areas were transferred to the MP density
map (see Fig. 2). Thereafter, the LMPOD was measured
using the Heidelberg Eye Explorer software. LMPOD was
compared between altered and normal area.
For statistical analysis, GraphPad Prism Software Version
5.02 was used. For analysis of difference in optical density
between locations within a group, the Mann–Whitney U test
was used. Findings with an error probability of p<0.05 were
considered statistically significant.
Results
In total, 63 eyes of 63 subjects were included in this
analysis, and 28 subjects were male, and 35 subjects
female. Age ranged from 54.0 to 93.7 years with a mean
age of 75.8±8.8 years.
ARM was found in 47 eyes, atrophic ARMD was found
in 16 eyes. Group 1 comprised 31 cases with focal increase
of FAF. Group 2 comprised 32 cases with a focal decrease
of FAF.
In group 1, the mean LMPOD in the area of increased
FAF was 0.073±0.083. Mean LMPOD of the adjacent area
of normal FAF was 0.075±0.074 as shown in Fig. 3. No
significant difference was found in the comparison of the
mean values (p=0.927).
In group 2, the area of decreased FAF exhibited a mean
LMPOD of –0.004±0.088. Mean LMPOD of the adjacent
area of normal FAF was 0.053±0.075 as shown in Fig. 3.
Areas of decreased FAF revealed significantly lower optical
densities (p=0.001) compared to adjacent areas of normal
FAF. The mean size of the FAF lesion was 0.1165 mm2 in
group 1 and 0.1266 mm2 in group 2, showing no significant
difference (p=0.847) as shown in Fig. 4. Measurement of
the central MP density revealed a mean value of 0.68±0.20
density units (DU) in group 1 and 0.60±0.20 DU in group
2 as shown in Fig. 4. A tendency to lower central MP
density in group 2 was found but no statistical significant
difference (p=0.103).
Discussion
Alterations in FAF imaging in connection with ARM and
ARMD have been investigated in numerous studies so far
[6, 11, 12, 23]. In contrast to normal background
fluorescence, hyper- and hypofluorescence seem to be focal
hallmarks of changes in health and metabolism of RPE and
photoreceptor cells. So far, increased FAF intensity in
monogenetic and multifactorial disease was primarily
attributed to the amount of accumulated RPE lipofuscin
[7, 8]. As the recent work of Sparrow et al. suggests, other
mechanisms might contribute significantly to focal hyper-
fluorescence [24]. Factors such as photooxidative modifi-
cation of RPE lipofuscin fluorophores or elevated
bisretinoid synthetic activity in disabled photoreceptor cells
are reported. N-retinylidene-N-reinylethanolamine (A2-E)
has been identified as a compound of lipofuscin with toxic
properties in terms of detergent effects and inhibition of
lysosomal function [25, 26]. Hypofluorescence is mainly
attributed to either atrophy of RPE cells or light absorption
by melanin pigmentation, hemorrhage, or intraretinal
exudates. Changes of FAF have a broad spectrum of
appearances. Mainly by description of morphologic fea-
tures, distinct patterns have been presented for classification
of FAF changes [27]. These patterns seem to offer a certain
predictive value for disease progression [23].
In search of a biomarker for assessment of individual
ARMD risk and early detection, MP is continuously
investigated. A variety of methods are available for the
non-invasive measurement of MP. The two-wavelength
autofluorescence densitometry used in this study has been
evaluated as a safe and highly repeatable method of
measurement [6]. Allowing not only for overall quantifica-
Fig. 2 Examples from group 1 (i.e., lesion of hyperfluorescence) and
group 2 (i.e., lesion of hypofluorescence) illustrating the measurement
of local macular pigment optical density. Above 488-nm fundus
autofluorescence (FAF) images. Below Macular pigment optical
density (MPOD) maps; 1 indicating the lesion, 2 indicating the
reference area
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tion of MP but also for analysis of distribution and
quantification in circumscribed areas is an advantage of
this method of MP imaging [20].
In this study, we investigated LMPOD at the site of
altered FAF in contrast to normal background FAF. In other
words, we investigated the impact of the underlying disease
on the signal at the two wavelengths to find a possible
colocalization of FAF and LMPOD alterations. For lesions
of focal increased FAF, we found no significant difference
in LMPOD when compared to adjacent areas of normal
FAF. The current concept implies that increased FAF is
caused by lipofuscin accumulation and metabolic alteration
in RPE and photoreceptor cells [24]. Our finding suggests
that this does not directly affect the distribution of MP. The
anatomical location of MP was investigated in earlier
studies on primate and human retinas [28, 29]. Deposition
of MP was linked mainly to the fibers of Henle within the
fovea and to the inner and outer plexiform layers in the
parafoveal region. In contrast to that, changes of early
ARM are mostly confined to the RPE, Bruch’s membrane,
and the choroid. With this separate anatomical location,
independence of both processes seems to be most likely for
lesions leading to hyperfluorescence in FAF imaging.
For lesions of focal-decreased FAF, the comparison to
normal FAF areas revealed a significantly lower optical
density of MP at this location. Apparently, processes
resulting in focal-reduced FAF might lead to a lack of MP
optical density. Hypofluorescence in FAF is believed to be
caused by reduced RPE metabolic activity, cell atrophy, or
thinning of the RPE monolayer because of underlying
drusen [30], increase of melanin content, or absorption of
FAF signal, e.g., by hemorrhage, edema, or crystalline
deposits. With RPE atrophy and possibly RPE thinning as
the main reason for reduced FAF intensity in our cases, one
might speculate that reduced metabolism and lack of RPE
cells might lead to decreased LMPOD by hindering
transport and storage. However, beside the various causes
of reduced FAF, one has to consider methodological
reasons for this finding as well: The measurement of MP
optical density by two-wavelength laser excitation is
dependent on a certain intensity of FAF. As levels of
extrafoveal L and Z are very low, the difference by
absorption of exciting laser light is presumably very small.
If a critical intensity of AF is undercut, e.g., by absence of
fluorophores, signal-to-noise ratio will decrease and mea-
surement will lead to an underestimation of MP optical
density. In this setting, the low intensity of FAF could be
the reason for a falsely low density of MP at this location.
Analysis of central MP density showed no significant
difference between group 1 and 2. However, a tendency to
lower values in group 2 can be suspected. The sum of
lesions of decreased FAF in group 2 could well have
influenced the central MP density to lower values.
MP distribution in topographical relation to retinal
pathology has been investigated before. As a common
finding in macular telangiectasia type 2, a reduction of
Fig. 3 Distribution of local
macular pigment optical density
(LMPOD) at the site of lesion vs.
background reference for group 1
(i.e., hyperfluorescence) and
group 2 (i.e., hypofluorescence)
Fig. 4 Size of assessed fundus
autofluorescence lesions in mm2
(left) and mean value of the
central macular pigment (MP)
optical density (OD) for group 1
and group 2, respectively
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central MP optical density was reported in several pub-
lications [31–33]. Involving the central 4° and a predom-
inant loss of Z, the reduction was found to coincide with the
disease epicenter temporal to the foveola. In Sjögren-
Larsson syndrome, an autosomal recessive hereditary
disorder, lack of central MP has recently been reported by
van der Veen et al. [34]. In conjunction with FAF changes,
the authors suggest a disturbed retinal MP metabolism,
presumably located in the Müller cells as the most probable
reason for the MP deficiency. Although correlating MP to
the location of pathologic changes, to our knowledge local
optical density of MP and focal FAF alterations have not
been investigated in an almost pixel-to-pixel comparison.
By the current conception, alterations of FAF are caused
by changes in metabolic activity of the RPE and photore-
ceptor cells. Our results indicate that areas of focal-
increased FAF have no influence on the factors determining
MP optical density at the very retinal location.
For lesions exhibiting focal-decreased FAF, our results
suggest a related reduction of MP optical density at this
retinal location, although the weakness of the method of
measurement clearly questions this finding.
Focal alterations of FAF are commonly observed in the
course of ARMD development. We assume that these
changes leave MP density and distribution unchanged for a
long time, until the late stage of the disease, with cell loss
and profound destruction of retinal layers occurring.
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